Lois Narr, DO
Family Medicine · Cambridge, MDNPI 1437265014
Payments from drug & device makers
Across 87 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$188
- Novo Nordisk$152
- Pfizer$149
- Lilly USA, LLC$145
- AstraZeneca$135
- Amgen$93
- plus $687 from 17 others
What the payments were for
- Food & beverage$1,53799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $188 |
| Novo Nordisk | 10 | $152 |
| Pfizer | 9 | $149 |
| Lilly USA, LLC | 8 | $145 |
| AstraZeneca | 9 | $135 |
| Amgen | 6 | $93 |
| Exact Sciences | 4 | $87 |
| GSK | 4 | $83 |
| AbbVie(2 entities) | 4 | $76 |
| Lundbeck LLC | 3 | $70 |
| Mylan Specialty L.p. | 2 | $64 |
| Novartis | 4 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Bayer | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Indivior Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$1,549 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $167,499 |
| EliquisApixaban | 108 | $87,508 |
| TrulicityDulaglutide | 48 | $78,638 |
| JardianceEmpagliflozin | 74 | $64,261 |
| MounjaroTirzepatide | 44 | $58,594 |
| JanuviaSitagliptin Phosphate | 63 | $45,366 |
| FarxigaDapagliflozin Propanediol | 28 | $32,407 |
| BelbucaBuprenorphine Hcl | 27 | $26,717 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $25,967 |
| RexultiBrexpiprazole | 12 | $17,756 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $15,465 |
| XareltoRivaroxaban | 21 | $13,235 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,695 |
| MyrbetriqMirabegron | 22 | $10,257 |
| EntrestoSacubitril/Valsartan | 11 | $7,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $152 | $167,499125 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $145 | $137,23192 claims |
| PfizerEliquis | $149 | $87,508108 claims |
| MerckJanuvia | $11 | $45,36663 claims |
| AstraZenecaFarxiga | $135 | $32,40728 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $52 | $17,75612 claims |
| Johnson & JohnsonXarelto | $12 | $13,23521 claims |
| GSKBreo Ellipta | $83 | $10,69520 claims |
| Astellas Pharma US IncMyrbetriq | $188 | $10,25722 claims |
| NovartisEntresto | $61 | $7,98611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Cambridge
- Casey ScottCambridge$88K
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
- Michael ObiefuneBaltimore$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.